Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program

REFERENCES

• Alford DP, LaBelle CT, Kretsch N et al., Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171:425–431.
   PubMed Web of Science ®Google Scholar
• Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131:127–135.
   PubMed Web of Science ®Google Scholar
• Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20:1038–1041.
   PubMed Web of Science ®Google Scholar
• Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5:146–150.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17:116–120.
   PubMed Web of Science ®Google Scholar
• Magura S, Lee S, Salsitz E, et al. Outcomes of buprenorphine maintenance in office-based practice. J Addict Dis. 2007;26:13–23.
   PubMed Web of Science ®Google Scholar
• Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106:56–60.
   PubMed Web of Science ®Google Scholar
• O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100–105.
   PubMed Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37:426–430.
   PubMed Web of Science ®Google Scholar
• Neumann AM, Blondell RD, Azadfard M, Nathan G, Homish GG. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment. Addict Behav. 2013;38:2724–2728.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96:1267–1278.
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Kosten TR. Buprenorphine for opiate addiction: potential economic impact. Drug Alcohol Depend. 2001;63:253–262.
   PubMed Web of Science ®Google Scholar
• Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. Pharmaco Economics. 2005;23:77–91.
   PubMed Web of Science ®Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess.. 2007;11(9):1–171, iii–iv.
   PubMed Web of Science ®Google Scholar
• Doran CM, Shanahan M, Mattick RP, Ali R, White J, Bell J. Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend. 2003;71:295–302.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Leff JA, Polsky D, Moore BA, Fiellin DA. Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care. J Gen Intern Med. 2012;27:669–676.
   PubMed Web of Science ®Google Scholar
• Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff (Millwood). 2011;30:1425–1433.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Buprenorphine prescribing practices and exposures reported to a poison center—Utah, 2002–2011. MMWR Morb Mort Wkly Rep. 2012;61:997–1001.
   PubMedGoogle Scholar
• Stein BD, Gordon AJ, Sorbero M, Dick AW, Schuster J, Farmer C. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend. 2012;123:72–78.
   PubMed Web of Science ®Google Scholar
• Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. Rockville: MD: Substance Abuse and Mental Health Services Administration; 2004. DHHS Publication No. (SMA) 04-3939. Available at: http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf. Accessed September 1, 2009.
   Google Scholar
• Magura S, Staines GL, Blankertz L, Madison EM. The effectiveness of vocational services for substance users in treatment. Subst Use Misuse. 2004;39:2165–2213.
   PubMed Web of Science ®Google Scholar
• Clark RE, Baxter JD, Barton BA, Aweh G, O'Connell E, Fisher WH. The impact of prior authorization on buprenorphine dose, relapse rates and cost for Massachusetts Medicaid beneficiaries with opioid dependence. Health Serv Res. 2014; 49:1964–1979.
   Google Scholar
• Iezzoni LI. Assessing quality using administrative data. Ann Intern Med. 1997;127(8 Pt 2):666–674.
   PubMed Web of Science ®Google Scholar
• Ray WA. Policy and program analysis using administrative databases. Ann Intern Med. 1997;127(8 Pt 2):712–718.
   PubMed Web of Science ®Google Scholar
• Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27:129–139.
   PubMed Web of Science ®Google Scholar
• Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(7 Suppl 1):S51–S55.
   PubMedGoogle Scholar
• Garnick DW, Hodgkin D, Horgan CM. Selecting data sources for substance abuse services research. J Subst Abuse Treat. 2002;22:11–22.
   PubMed Web of Science ®Google Scholar
• Garnick DW, Lee MT, Chalk M, et al. Establishing the feasibility of performance measures for alcohol and other drugs. J Subst Abuse Treat. 2002;23:375–385.
   PubMed Web of Science ®Google Scholar
• Garnick DW, Horgan CM, Chalk M. Performance measures for alcohol and other drug services. Alcohol Res Health. 2006;29:19–26.
   PubMedGoogle Scholar
• Garnick DW, Lee MT, Horgan CM, Acevedo A, Washington Circle Public Sector W. Adapting Washington Circle performance measures for public sector substance abuse treatment systems. J Subst Abuse Treat. 2009;36:265–277.
   PubMed Web of Science ®Google Scholar
• Crevecoeur-MacPhail D, Ransom L, Myers AC, et al. Inside the black box: measuring addiction treatment services and their relation to outcomes. J Psychoactive Drugs. 2010;Suppl 6:269–276.
   PubMedGoogle Scholar
• Thomas CP, Garnick DW, Horgan CM, et al. Advancing performance measures for use of medications in substance abuse treatment. J Subst Abuse Treat. 2011;40:35–43.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Garnick DW, Horgan CM, Miller K, Harris AH, Rosen MM. Establishing the feasibility of measuring performance in use of addiction pharmacotherapy. J Subst Abuse Treat. 2013;45:11–18.
   PubMed Web of Science ®Google Scholar
• Kronick R, Gilmer T, Dreyfus T, Lee L. Improving health-based payment for Medicaid beneficiaries: CDPS (Chronic Illness and Disability Payment System). Health Care Financing Rev. 2000;21:29–64.
   PubMedGoogle Scholar
• American Medical Association. CPT—Current Procedural Terminology. Available at: http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt.page?. Accessed May 6, 2015.
   Google Scholar
• Centers for Medicare and Medicaid Services. The Healthcare Common Procedure Coding Set (HCPCS). Available at: http://www.ama-assn.org/ama/pub/physician-resources/solutions-managing-your-practice/coding-billing-insurance/cpt.page?. Accessed May 6, 2015.
   Google Scholar
• Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24:226–232.
   PubMed Web of Science ®Google Scholar
• Sohler NL, Li X, Kunins HV, et al. Home-versus office-based buprenorphine inductions for opioid-dependent patients. J Subst Abuse Treat. 2010;38:153–159.
   PubMed Web of Science ®Google Scholar
• Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav. 2010;35:537–540.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Morb Mort Wkly Rep. 2006;55(RR14):1–17.
   PubMedGoogle Scholar
• Wisniewski AM, Dlugosz MR, Blondell RD. Reimbursement and practice policies among providers of buprenorphine-naloxone treatment. Subst Abus. 2013;34:105–107.
   PubMed Web of Science ®Google Scholar
• Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23:1393–1398.
   PubMed Web of Science ®Google Scholar
• Thomas CP, Reif S, Haq S, Wallack SS, Hoyt A, Ritter GA. Use of buprenorphine for addiction treatment: perspectives of addiction specialists and general psychiatrists. Psychiatr Serv. 2008;59:909–916.
   PubMed Web of Science ®Google Scholar
• Kosten T, Oliveto A, Feingold A, et al. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003;70:315–325.
   PubMed Web of Science ®Google Scholar
• Montoya ID, Schroeder JR, Preston KL, et al. Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat. 2005;28:247–254.
   PubMed Web of Science ®Google Scholar
• Ling W, Hillhouse M, Ang A, Jenkins J, Fahey J. Comparison of behavioral treatment conditions in buprenorphine maintenance. Addiction. 2013;108:1788–1798.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry. 2011;68:1238–1246.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Barry DT, Sullivan LE, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126:74.e11–e17.
   PubMedGoogle Scholar
• Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365–374.
   PubMed Web of Science ®Google Scholar
• Clark RE, Baxter JD. Responses of state Medicaid programs to buprenorphine diversion: doing more harm than good? JAMA Intern Med. 2013;173:1571–1572.
   PubMed Web of Science ®Google Scholar
• The Avisa Group and the Treatment Research Institute (TRI). Advancing access to addiction medication: implications for opioid treatment. Available at: http://www.asam.org/docs/advocacy/Implications-for-Opioid-Addiction-Treatment. Published 2013. Accessed July 17, 2013.
   Google Scholar
• Humphreys K, Trafton JA, Oliva EM. Does following research-derived practice guidelines improve opiate-dependent patients' outcomes under everyday practice conditions? Results of the multisite opiate substitution treatment study. J Subst Abuse Treat. 2008;34:173–179.
   PubMed Web of Science ®Google Scholar
• Barnett PG, Trafton JA, Humphreys K. The cost of concordance with opiate substitution treatment guidelines. J Subst Abuse Treat. 2010;39:141–149.
   PubMed Web of Science ®Google Scholar